Terumo Corporation · TSE:4543
Terumo — Investor Presentation (December 2021)
14 slides from Terumo's investor presentation, Dec 16, 2021
Slide 1: Terumo Blood and Cell Technologies: 5-Year Growth Strategy with a 10-Year Vision
Celebrating our 100th founding anniversary: 5-Year Growth Strategy with a 10-Year Vision 04 | Terumo Blood and Cell Technologies Antoinette Gawin, President ©TERUMO CORPORATION 1 / 13
Slide 2: Safe Harbor for Forward-Looking Statements and Use of Document
Safe Harbor for Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future even
Slide 3: Vision for our 5-Year Growth Strategy
Vision for our 5-Year Growth Strategy Our Aspiration Provide compelling and accessible innovations globally that unlock the power of blood and cells to improve patient outcomes and serve unmet medical needs How this will be achieved By inspiring and engaging our associates, we will optimize quality
Slide 4: Looking Back on Current Mid- to Long-term Growth Strategy
Looking Back on Current Mid- to Long-term Growth Strategy Modernized our foundation and returned to growth while investing in our future Achievements Adjusted operating profit % ⚫ SHIFTED INVESTMENT TO GROWTH AREAS 17.4% 16.1% ▪ Launching in source plasma market 14.4% 14.9% 14.0% ▪ Invested in cell
Slide 5: Key Shifts in Market
Key Shifts in Market Market Dynamics Strategic Implications Market ▪ Establish a significant footprint in cell therapy; improve ▪ Cell therapy commercialization our partnership capabilities increasing competition ▪ Leverage service platform and digital capabilities to ▪ Integrated solutions for data
Slide 6: Common Technology Serves Diverse Customers
Common Technology Serves Diverse Customers Services and software coupled with trusted technologies and delivery systems differentiate us Plasma Therapeutic Autologous Blood Centers Cell Therapy Innovations Apheresis Biologics Business Area Trima Reveos TOMEs Innovative Ecosystem Spectra Quantum FINI
Slide 7: 5-Year Growth Strategy: Terumo Blood and Cell Technologies
5-Year Growth Strategy: Terumo Blood and Cell Technologies Strategic investments will reshape our portfolio and differentiate our competitive position ▪ Plasma – disrupt market and expand presence beyond US Blood and Beyond ▪ Cell Therapy – expand market focus and connect patient and cell journey ▪
Slide 8: Innovate Source Plasma Market
Plasma Innovations Innovate Source Plasma Market Innovation in device and ecosystem supports growing demand for plasma-derived therapies Built ecosystem to address unmet needs Transforming business across organization State-of-art Gaining significant market traction Automation Innovative Manufacturi
Slide 9: Cell Therapy and Service Innovation
Cell Therapy Cell Therapy and Service Innovation Facilitate the journey of life-saving cells from patient collection through the ultimate transfusion Patient journey Testing and Cell Collection and Patient Coordination Preparation Spectra Optia Market: ▪ Crowded, undefined market Testing and Collect
Slide 10: Enabling Technology Saving Lives through Apheresis
Therapeutic Apheresis Enabling Technology Saving Lives through Apheresis Potential life-saving therapies delivered by the Optia … The patient care journey informs innovation Unlock the therapeutic potential Innovative technologies combined with Myasthenia gravis apheresis changing the standard of ca
Slide 11: Shape Future Across Diverse Care Continuum
Blood Centers Shape Future Across Diverse Care Continuum Unmet local needs inform unique business models and growth in blood center business Continuum of transfusion therapies ❶ Recruit ❷ Collect ❸ Process ❹ Deliver ❺ Treat Leapfrog in emerging markets Transform advanced blood centers ▪ Automate pro
Slide 12: Revenue and Profit Overview
Revenue and Profit Overview Revenue Adjusted Operating Profit Near double-digit growth Beyond 20% (Adjusted operating profit %) FY16 FY21 FY26 FY16 FY21 FY26 Blood and Beyond Operational Excellence ▪ Plasma Innovations Disrupt the market ▪ Utilize modernized enterprise platforms ▪ Cell therapy Doubl
Slide 13: Everything Begins with a Drop of Blood
Everything Begins with a Drop of Blood Follow the Collection to Treat the Patient Access to therapies Safe and adequate blood Industry-leading therapeutic apheresis Trusted pathogen reduction system Clinical data | Reimbursement | Mirasol Government affairs | Regional Spectra 24/7 training | Care de
Slide 14: Terumo
~“TERUMO